List of Excipients in Branded Drug PENICILLIN G POTASSIUM

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Baxter Healthcare Corporation	PENICILLIN G POTASSIUM	penicillin g	0338-1025	DEXTROSE MONOHYDRATE
Baxter Healthcare Corporation	PENICILLIN G POTASSIUM	penicillin g	0338-1025	HYDROCHLORIC ACID
Baxter Healthcare Corporation	PENICILLIN G POTASSIUM	penicillin g	0338-1025	SODIUM HYDROXIDE
Baxter Healthcare Corporation	PENICILLIN G POTASSIUM	penicillin g	0338-1025	TRISODIUM CITRATE DIHYDRATE

Generic Drugs Containing PENICILLIN G POTASSIUM

Company	Ingredient	NDC	Excipient
Sandoz Inc	penicillin g potassium	0781-6135	CITRIC ACID MONOHYDRATE
Sandoz Inc	penicillin g potassium	0781-6135	SODIUM CITRATE
Sagent Pharmaceuticals	penicillin g potassium	25021-153	SODIUM CITRATE
HF Acquisition Co LLC DBA HealthFirst	penicillin g potassium	51662-1689	SODIUM CITRATE

What are the Most Frequently-Used Excipients in PENICILLIN G POTASSIUM?

# Of NDCs	Excipient
1	CITRIC ACID MONOHYDRATE
7	SODIUM CITRATE

Penicillin G Potassium Excipient Strategy and Commercial Opportunities

Last updated: November 3, 2026

Penicillin G potassium is an off-patent, sterile injectable antibiotic with limited opportunity for conventional formulation exclusivity. Commercial value is concentrated in reliable sterile manufacturing, differentiated ready-to-use presentations, potassium-load management, storage stability, pediatric dosing, hospital supply contracts, and access to markets where injectable penicillin remains an essential medicine. The active ingredient is benzylpenicillin potassium, marketed primarily as a powder for injection and reconstitution before intravenous or intramuscular administration.

What is the FDA status of penicillin G potassium injection?

Penicillin G potassium injection is an established prescription product used for serious infections caused by susceptible organisms, including streptococcal infections, meningococcal disease, syphilis-related indications in selected clinical settings, and other infections where high-dose parenteral penicillin is appropriate.[1]

Attribute	Penicillin G potassium
Active ingredient	Benzylpenicillin potassium
Drug class	Natural penicillin antibiotic
Route	Intravenous or intramuscular injection
Dosage form	Sterile powder for reconstitution; selected premixed presentations may be available by market
FDA regulatory pathway	Established drug; generic injectable competition
Oral suitability	Poor, because benzylpenicillin is acid labile
Primary customers	Hospitals, public-health systems, wholesalers, government procurement agencies
Patent position	Active-ingredient patent protection expired
Main commercial barrier	Sterile manufacturing, supply reliability, quality systems, and procurement access

The FDA-approved labeling identifies penicillin G potassium as a sterile crystalline powder that must be reconstituted before administration. The label also identifies clinically important potassium exposure, which becomes material at high doses or in patients with renal impairment, hyperkalemia risk, or cardiac disease.[1]

When does penicillin G potassium lose exclusivity?

Penicillin G potassium lost compound-level exclusivity decades ago. There is no commercially meaningful remaining exclusivity period based on the active ingredient.

Unlike newer small-molecule products, penicillin G potassium does not depend on a current composition-of-matter patent, new chemical entity exclusivity, or data-exclusivity period. Generic manufacturers can compete through abbreviated new drug applications, subject to FDA requirements for identity, strength, quality, sterility, labeling, and manufacturing controls.[2]

Does penicillin G potassium have active Orange Book patents?

Penicillin G potassium injection has no significant active Orange Book patent barrier identified in the public FDA Orange Book framework for established injectable products.[2] The commercial question is therefore not whether a generic can enter after patent expiry. It is whether the manufacturer can produce a sterile product consistently and secure distribution.

Paragraph IV litigation is not a central risk for the established penicillin G potassium market. A manufacturer pursuing a conventional abbreviated application would generally face a low patent challenge burden compared with products protected by formulation, device, or method-of-use patents.

What excipients are used in penicillin G potassium injection?

The core injectable formulation is unusually simple. Many commercial presentations contain penicillin G potassium as the active drug with no conventional functional excipient in the vial. The powder is reconstituted with Sterile Water for Injection or a compatible infusion solution before use.[1]

Excipient and presentation matrix

Formulation element	Technical purpose	Commercial relevance
Penicillin G potassium	Active pharmaceutical ingredient and potassium salt	Provides water solubility for injection
Sterile Water for Injection	Reconstitution vehicle	Standard hospital preparation option
Sodium chloride injection	Diluent and tonicity adjustment	Useful for intravenous infusion protocols
Dextrose injection	Alternative infusion vehicle	Supports hospital compatibility requirements
Buffer system	pH control where justified	May improve stability but increases regulatory and compatibility burden
Chelating agent	Potential metal-ion control	Limited opportunity because injectable safety and compatibility must be demonstrated
Antioxidant	Oxidation control	Requires strong stability rationale and impurity assessment
Preservative	Multidose microbial control	Generally unattractive for high-risk neonatal, pediatric, and intravenous use
Container-closure system	Moisture and oxygen protection	One of the strongest practical differentiation areas
Lyophilization or controlled drying	Improves solid-state and reconstitution performance	Can support shelf-life and supply-chain improvements

The highest-value formulation decisions are often outside the liquid itself. Moisture ingress, vial closure performance, reconstitution time, powder cake quality, particulate control, and compatibility with infusion systems directly affect hospital usability.

What excipient strategy is technically attractive?

A strong development strategy should preserve the simple, low-risk formulation unless a measurable clinical or operational benefit justifies change.

1. Use a minimal-excipient sterile powder

The lowest-risk platform is a sterile powder consisting primarily of penicillin G potassium in a moisture-protective vial. This approach minimizes:

• Excipient-related toxicity
• New extractables and leachables
• pH-shift risk
• Compatibility problems with infusion solutions
• Additional impurity pathways
• Regulatory questions for an established injectable

The principal development work should focus on solid-state characterization, moisture control, vial headspace, closure integrity, reconstitution time, and stability-indicating analytical methods.

2. Optimize the diluent package

A commercial kit containing the drug vial and a validated diluent can improve hospital workflow. Options include:

• Sterile Water for Injection
• 0.9% sodium chloride injection
• 5% dextrose injection
• Smaller-volume diluents for pediatric or neonatal dosing

The selected diluent should be evaluated for chemical stability, particulate formation, precipitation, adsorption to infusion tubing, and in-use dating. The package should not imply compatibility with every infusion solution. Labeling must specify validated concentrations, storage conditions, and administration windows.

3. Develop ready-to-use liquid or premixed products selectively

A ready-to-use presentation can reduce pharmacy compounding steps and medication-preparation errors. It also creates a stronger commercial proposition than another conventional powder vial.

The main technical barriers are:

• Hydrolysis of the beta-lactam ring
• Temperature sensitivity
• pH-dependent degradation
• Concentration-dependent stability
• Container-closure permeability
• Sterility maintenance during extended storage
• Compatibility with bags, ports, tubing, and automated dispensing systems

A liquid product may require a buffer, specialized packaging, refrigerated distribution, or a shorter shelf life. These requirements can erase the operational benefit unless the product achieves a meaningful room-temperature shelf life and a clear hospital-use advantage.

4. Consider lyophilization or controlled crystalline powder engineering

A highly uniform powder can improve reconstitution and reduce vial-to-vial variability. Lyophilization may be useful where the target market requires rapid dissolution, long storage, or improved shipping conditions. It is less attractive if it increases manufacturing cost without extending shelf life or reducing preparation time.

For a low-price antibiotic, powder engineering must be linked to a procurement benefit. Faster reconstitution alone may not justify a material increase in cost unless hospitals, emergency departments, or public-health buyers quantify the labor and error reduction.

What formulations are protected by penicillin G potassium patents?

The commercial formulation landscape is unlikely to support broad exclusionary patent protection. Potentially protectable subject matter includes:

• A defined stable liquid composition
• A specific pH and buffer range
• A low-moisture crystalline form
• A reconstitution system with controlled concentration
• A container-closure configuration
• A premixed infusion bag with defined stability
• A manufacturing process that reduces degradation products
• A specific pediatric or neonatal dosing presentation

These claims would face novelty and obviousness pressure because penicillin G potassium has been used clinically for many decades. A patent strategy should therefore target narrow, data-supported combinations rather than broad claims covering the active ingredient and routine excipients.

Potential patent value is highest where the formulation solves a documented problem, such as:

1. Stable room-temperature storage.
2. Rapid reconstitution without foaming or visible particles.
3. Reduced adsorption in infusion systems.
4. Lower potassium exposure through a different salt or concentration strategy, where clinically and regulatorily feasible.
5. Extended in-use stability after dilution.
6. A package designed for emergency administration or pediatric dosing.

A formulation patent would not automatically block conventional generic powder products. Its commercial effect would depend on whether the protected presentation captures hospital purchasing volume.

How important is potassium management in product design?

Potassium content is a central product attribute. Each unit of penicillin G potassium carries potassium into the administered dose. High-dose treatment can create a clinically relevant potassium burden, particularly in patients with renal dysfunction or existing electrolyte abnormalities.[1]

This creates several product-development opportunities:

• Lower-concentration presentations that permit more precise dosing.
• Dose-calibrated vials for pediatric and neonatal use.
• Clear potassium-content labeling by million units and by vial.
• Packaging that reduces calculation errors.
• Alternative penicillin salts where clinically appropriate.
• Decision-support materials for hospital pharmacy systems.

A lower-potassium formulation could have commercial value, but changing the counterion would create a different active pharmaceutical ingredient and a more complex regulatory pathway. The opportunity is therefore larger than a simple excipient change but carries greater development and comparability risk.

What manufacturing and IP barriers affect commercial entry?

The active ingredient is inexpensive relative to the manufacturing controls required for an injectable antibiotic. Entry barriers include:

• Sterile API production
• Aseptic filling or validated terminal sterilization strategy where applicable
• Endotoxin control
• Sterility assurance
• Particulate limits
• Moisture-sensitive powder handling
• Container-closure integrity
• Beta-lactam segregation and facility controls
• Validated cleaning to prevent cross-contamination
• Reliable supply of sterile vials, stoppers, and aluminum seals
• Inspection readiness and batch-release testing

Penicillin manufacturing requires particular attention to cross-contamination controls because beta-lactam residues can create serious quality and patient-safety risks. A manufacturer may need dedicated areas, validated containment, or specialized campaign controls depending on the facility design and regulatory expectations.[3]

The practical moat is operational rather than patent-based. A supplier that avoids backorders, maintains validated release cycles, and supports hospital contracts can outperform a lower-cost but unreliable competitor.

Which companies are competing in the penicillin G potassium market?

Competition is fragmented across branded legacy suppliers, generic injectable manufacturers, contract manufacturers, and regional distributors. The relevant competitive set changes by country because injectable penicillin procurement is often controlled by national tenders or public-health purchasing systems.

Competition typically occurs on:

• Price per million units
• Available vial strengths
• Annual supply commitments
• Shortage performance
• Shelf life at shipment
• Refrigeration requirements
• Packaging configuration
• Regulatory registrations
• Government tender eligibility
• Pharmacovigilance and recall history

The product competes indirectly with penicillin G sodium, penicillin G benzathine, penicillin G procaine, and other beta-lactam antibiotics. These products are not interchangeable in route, pharmacokinetics, salt form, indications, or dosing frequency.

How does penicillin G potassium compare with related penicillin products?

Product	Primary use profile	Key formulation distinction	Commercial implication
Penicillin G potassium	High-dose parenteral treatment	Potassium salt, usually powder for injection	Hospital and acute-care product
Penicillin G sodium	Parenteral treatment	Sodium salt	Alternative where sodium load is preferred
Penicillin G benzathine	Long-acting intramuscular treatment	Poorly soluble depot suspension	Different clinical use and administration model
Penicillin G procaine	Longer-acting intramuscular treatment	Procaine salt suspension	Different pharmacokinetics and tolerability
Penicillin V potassium	Oral treatment	Acid-stable phenoxymethylpenicillin	Not a substitute for injectable benzylpenicillin

The most direct product comparison is with penicillin G sodium. Selection can depend on electrolyte burden, clinical protocol, procurement price, and local availability. Penicillin G benzathine is a separate commercial category and should not be treated as a formulation substitute for penicillin G potassium.

What licensing deals and partnerships are commercially relevant?

Large originator-style licensing transactions are unlikely for an off-patent penicillin salt. The stronger partnership opportunities are supply and manufacturing agreements:

• Regional contract manufacturing
• Dual-source API agreements
• Government framework contracts
• Hospital group purchasing arrangements
• Emergency stockpile programs
• Technology transfer for sterile filling
• Local registration partnerships in emerging markets
• Co-packaging agreements for vial-and-diluent kits

A licensee with an established sterile injectable facility can create value by reducing time to market and improving regulatory execution. In lower-income markets, local fill-finish capacity and tender eligibility may matter more than proprietary excipient technology.

What generic launch scenarios exist for penicillin G potassium?

Conventional powder vial

This is the lowest-risk launch. The product competes on cost, supply reliability, vial strengths, and regulatory coverage. It is unlikely to generate strong differentiation but can achieve durable institutional demand.

Vial-and-diluent kit

This model improves pharmacy workflow and can support pediatric, emergency, and government procurement channels. The kit may qualify for formulation, packaging, or combination-product claims if the design is technically distinctive.

Ready-to-use infusion product

This has the highest commercial differentiation but also the greatest stability, packaging, and manufacturing burden. It is most attractive where hospitals pay for reduced preparation time and medication-safety improvements.

Pediatric precision-dose platform

Smaller vial strengths, calibrated diluents, and clearer potassium labeling could support neonatal and pediatric use. The opportunity is operational rather than patent-driven.

Emerging-market supply platform

A manufacturer with stable supply, local registrations, and competitive tender pricing can build share in regions where injectable benzylpenicillin remains clinically important and supply interruptions are frequent.

What is the revenue exposure and market outlook?

Publicly available information does not support a reliable standalone global revenue estimate for penicillin G potassium because sales are distributed across generic suppliers, hospital contracts, government tenders, and country-specific presentations. The product is a mature, low-price medicine rather than a high-margin specialty pharmaceutical.

Revenue exposure is most sensitive to:

• Hospital and government tender wins
• Product shortages
• Sterile manufacturing capacity
• API availability
• Regulatory registrations
• Vial-strength mix
• Geographic supply agreements
• Contract renewal cycles

The highest-return strategy is generally not a broad patent campaign. It is a focused platform combining dependable supply with one or more measurable workflow improvements.

What is the patent strength of penicillin G potassium?

Patent strength is low for the base product and potentially moderate for a validated differentiated presentation.

Asset type	Expected strength
Composition-of-matter patent	None of practical current value
Conventional powder formulation	Low
Routine diluent combination	Low
Narrow stability composition	Moderate if supported by unexpected data
Ready-to-use product	Moderate, depending on stability and claim scope
Container-closure system	Moderate where functionally distinctive
Manufacturing process	Moderate but vulnerable to design-around
Pediatric dosing package	Low to moderate
Brand or supply contract	Commercially useful but not patent exclusivity

A successful patent filing would need comparative data against standard benzylpenicillin potassium formulations. Stability results, impurity reduction, reconstitution performance, and real-world compatibility data are more valuable than broad excipient lists.

Key Takeaways

• Penicillin G potassium is an off-patent sterile injectable with no meaningful active-ingredient exclusivity.
• The core formulation is usually a simple sterile powder for reconstitution.
• Excipient additions should be limited to solutions that improve stability, compatibility, storage, or administration.
• Ready-to-use liquids, vial-and-diluent kits, and pediatric presentations offer the clearest commercial differentiation.
• Potassium exposure is a clinically relevant design and labeling issue.
• Sterile manufacturing, beta-lactam containment, supply reliability, and procurement access are stronger barriers than patents.
• Formulation patents are possible but should target narrow, data-supported stability or delivery improvements.
• The best commercial strategy is a reliable generic platform with operational differentiation rather than an originator-style exclusivity model.

FAQs

Can penicillin G potassium be formulated as a preservative-containing multidose injection?

It can be evaluated, but preservatives are generally unattractive for high-risk intravenous, neonatal, and pediatric use. A single-dose sterile vial is usually a lower-risk commercial design.

Is penicillin G potassium compatible with normal saline and dextrose?

Both sodium chloride injection and dextrose injection are used as reconstitution or infusion vehicles in clinical practice, subject to product-specific labeling, concentration, stability, and administration requirements.[1]

Can a new excipient create patent protection for penicillin G potassium?

A new excipient alone rarely creates strong protection. Patent value depends on a specific composition that produces a demonstrated and non-obvious technical benefit, such as materially improved stability or reconstitution.

Is penicillin G potassium suitable for a premixed infusion bag?

A premixed bag is technically possible, but chemical stability, container compatibility, sterility, storage temperature, and in-use dating determine whether the product is commercially viable.

Does penicillin G potassium compete directly with Bicillin L-A?

No. Bicillin L-A contains penicillin G benzathine and is a long-acting intramuscular suspension. Penicillin G potassium is a water-soluble parenteral product used for different dosing and treatment contexts.

References

1. Pfizer Laboratories. (2023). Penicillin G potassium for injection, USP: Prescribing information. DailyMed, U.S. National Library of Medicine.

2. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. U.S. Food and Drug Administration. (2016). Current good manufacturing practice for drugs: Quality systems approach. FDA.

4. World Health Organization. (2023). WHO model list of essential medicines: 23rd list. World Health Organization.

5. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP.